MALAT1 and primary cutaneous T-cell non-Hodgkin lymphoma: Therefore, we started with an evaluation of MALAT1 levels in the serum of CTCL patients (n=10), as compared to the levels of MALAT1 in the serum of healthy control volunteers (n=8).